group
rotavirus
rva
lead
caus
gastroenter
malnutrit
diarrhea
young
children
anim
human
rva
estim
caus
death
per
year
children
year
age
mostli
develop
countri
death
rva
infect
preval
develop
nation
patient
may
alway
receiv
adequ
medic
attent
quickli
enough
current
two
commerci
avail
vaccin
market
rotateq
merck
pentaval
humanbovin
reassort
live
attenu
oral
vaccin
rotarix
glaxosmithklin
liveattenu
human
rva
vaccin
vaccin
appear
promis
prevent
rva
diarrhea
howev
effect
particular
strain
viru
high
cost
product
high
probabl
manifest
side
effect
particular
vaccinederiv
transmiss
rva
immunocompromis
patient
synthet
compound
ribavirin
cimetidin
famotidin
dipyridamol
nifedipin
isoprinosin
shown
inhibit
rva
infect
compar
synthet
compound
natur
compound
diotahedr
smecta
tea
pine
seed
shell
extract
cacao
pigment
sophora
flavescen
extract
stevia
rebaudiana
identifi
ideal
candid
antirotavir
drug
develop
countri
effect
cheaper
minim
without
toxic
sideeffect
also
note
compound
found
human
milk
soy
infant
formul
effect
inhibit
rotaviru
infect
potenti
compon
found
high
level
soybas
infant
formul
isoflavon
vitro
studi
reveal
genistin
mixtur
isoflavon
inhibit
rotaviru
infect
modul
viru
attach
postbind
step
high
level
antivir
activ
found
relat
mucin
found
human
milk
vitro
vivo
studi
show
variat
milk
mucin
glycoprotein
may
correl
differ
level
protect
infect
gastrointestin
pathogen
lactadherin
mucinassoci
glycoprotein
also
found
specif
inhibit
rotaviru
replic
vitro
vivo
licoric
dri
process
glycyrrhiza
radix
use
treatment
peptic
ulcer
diseas
constip
cough
diseas
sinc
antiqu
addit
licoric
extract
gener
recogn
safe
use
flavor
sweeten
agent
tobacco
chew
gum
candi
toothpast
beverag
bioactiv
constitut
licoric
root
saponin
flavonoid
isoflavon
coumarin
stilbenoid
miscellan
compound
compound
exert
mani
use
pharmacolog
properti
includ
anticanc
antidiabet
antiinflammatori
antimalaria
antibacteri
antioxid
estrogen
activ
compound
extract
glycyrrhiza
speci
show
antivir
activ
via
inhibit
viru
absorpt
replic
influenza
viru
sever
acut
respiratori
syndrom
sar
coronaviru
hepat
ac
virus
havhcv
epstein
barr
viru
human
immunodefici
viru
hiv
japanes
enceph
viru
moreov
compound
known
modul
virusinduc
inflammatori
respons
previou
studi
polyphenol
compound
root
glycyrrhiza
uralensi
g
uralensi
exert
vitro
antirva
activ
inhibit
viral
absorpt
viral
replic
anoth
vitro
studi
also
suggest
acid
aglycon
product
glycyrrhizin
hydrolysi
inhibit
rotaviru
entri
cell
howev
littl
evid
whether
compound
inhibit
rva
infect
anim
model
aim
studi
investig
influenc
g
uralensi
extract
gue
rvainduc
diarrhea
fecal
rva
shed
rvainduc
histolog
lesion
chang
rvainduc
cytokin
express
rvainduc
cellular
signal
event
colostrumsdepriv
piglet
result
studi
suggest
gue
cure
rotavir
enter
coordin
antivir
antiinflammatori
effect
determin
effect
dose
gue
rvainduc
diarrhea
colostrumsdepriv
piglet
oral
given
mgml
mgml
mgml
control
piglet
mockinocul
mocktreat
show
diarrhea
throughout
experiment
period
wherea
piglet
inocul
rva
alon
show
diarrhea
day
postinocul
dpi
diarrhea
persist
termin
experi
piglet
treat
mgml
mgml
continu
show
diarrhea
termin
experi
figur
piglet
treat
mgml
gue
exhibit
decreas
fecal
consist
score
dpi
diarrhea
cure
dpi
figur
evalu
influenc
gue
fecal
rva
shed
viral
rna
copi
number
fecal
sampl
individu
quantifi
enabl
comparison
mockedtr
treat
group
piglet
treat
mgml
mgml
gue
show
improv
fecal
viru
shed
remain
high
termin
experi
comparison
viru
inocul
mockedtr
piglet
figur
piglet
treat
mgml
reveal
rapid
decreas
viral
copi
number
fecal
sampl
compar
viru
inocul
mockedtr
group
figur
determin
influenc
gue
rvainduc
histolog
lesion
chang
small
intestin
intestin
sampl
collect
experiment
piglet
histolog
chang
small
intestin
sampl
experiment
group
summar
tabl
mockinocul
group
show
long
slender
villi
short
crypt
small
intestin
figur
virusinocul
piglet
mark
villi
atrophi
crypt
hyperplasia
figur
compar
sever
histolog
chang
small
intestin
piglet
inocul
rva
alon
piglet
given
mgml
mgml
gue
exhibit
gradual
improv
lesion
chang
figur
remark
piglet
receiv
mgml
gue
show
mark
improv
small
intestin
lesion
figur
like
control
group
piglet
treat
variou
concentr
gue
alon
normal
villi
crypt
small
intestin
figur
rel
mrna
express
use
specif
primer
pair
jnk
quantifi
realtim
pcr
assay
sampl
duodenum
jejunum
ileum
splenocyt
collect
group
mrna
express
level
jnk
compar
mocktreat
piglet
rva
diarrhea
higher
mrna
express
level
jnk
duodenum
jejunum
ileum
splenocyt
compar
normal
piglet
figur
dosedepend
gue
treatment
reduc
express
level
duodenum
jejunum
ileum
splenocyt
signific
downregul
observ
mgml
gue
treatment
group
figur
highli
signific
linear
effect
gue
reduc
mrna
express
jnk
nfkb
observ
duodenum
jejunum
ileum
splenocyt
use
polynomi
orthogon
contrast
data
shown
like
control
group
piglet
treat
gue
alon
regardless
concentr
mgml
show
basal
level
jnk
express
duodenum
jejunum
ileum
splenocyt
figur
realtim
rtpcr
assay
primer
pair
specif
perform
duodenum
jejunum
ileum
splenocyt
sampl
group
rel
mrna
express
level
compar
normal
mockinocul
guetreat
group
mgml
show
basal
level
mrna
express
duodenum
jejunum
ileum
splenocyt
figur
howev
mocktreat
piglet
rva
diarrhea
higher
mrna
level
compar
normal
piglet
interestingli
guetreat
group
rva
diarrhea
show
gradual
decreas
cytokin
dosedepend
manner
tissu
figur
analysi
orthogon
contrast
show
linear
data
reduc
mrna
express
ifn
ifn
tnf
conjunct
increas
amount
gue
duodenum
jejunum
ileum
splenocyt
data
shown
spite
intens
effort
prevent
control
rva
infect
still
major
global
problem
high
morbid
mortal
particularli
develop
countri
therefor
inexpens
effect
natur
compound
food
herbal
product
ideal
candid
use
prevent
therapeut
drug
rva
diarrhea
develop
countri
previous
demonstr
polyphenol
compound
isol
root
g
uralensi
vitro
antirva
activ
recent
acid
known
inhibit
rotaviru
replic
cultur
result
prompt
us
present
evalu
antirva
activ
gue
anim
model
number
studi
conduct
use
neonat
pig
model
studi
vaccin
passiv
antibodi
ab
treatment
develop
immun
respons
rotaviru
infect
moreov
similar
gastrointestin
physiolog
immun
system
piglet
human
infant
make
suitabl
anim
model
test
efficaci
antirotavir
drug
candid
present
studi
colostrumsdepriv
piglet
obtain
sow
hysterectomi
maintain
isol
unit
use
rva
anim
model
model
exactli
show
diarrhea
dpi
oral
inocul
porcin
rva
strain
select
porcin
strain
studi
sinc
genotyp
constel
porcin
human
rotavirus
similar
suggest
share
ancestor
among
virusinocul
gue
treat
group
gue
dose
mgml
administ
test
anim
complet
cure
rva
diarrhea
antirva
effect
gue
also
demonstr
signific
improv
intestin
lesion
score
fecal
viru
shed
result
suggest
herbal
medicin
may
potent
medic
cure
rva
diarrhea
human
anim
recent
studi
rotavirus
detect
extraintestin
organ
serum
sampl
rotavirusinfect
anim
human
futur
studi
therefor
effect
gue
point
address
although
precis
mechan
gue
cure
rva
diarrhea
colostrumsdepriv
piglet
unknown
divers
pathway
may
particip
particular
interest
polyphenol
compound
isol
root
g
uralensi
inhibitori
effect
rva
activ
cultur
cell
block
viral
adsorpt
cell
viru
replic
cell
present
vivo
studi
gue
complet
cure
diarrhea
significantli
improv
fecal
viru
shed
histolog
lesion
chang
small
intestin
like
vitro
data
polyphenol
compound
gue
may
inhibit
viru
replic
villou
epithelium
small
intestin
rva
mainli
replic
inhibitori
activ
may
result
mark
reduct
viru
excret
infect
cell
small
intestin
lumen
anoth
interest
find
show
acid
metabolit
glycyrrhizin
reduc
yield
infecti
viru
viral
protein
level
interf
rotaviru
replic
step
subsequ
viru
entri
anoth
possibl
vivo
inhibitori
mechan
polyphenol
compound
gue
may
bind
sialic
acid
receptor
rva
cell
surfac
small
intestin
villi
consequ
virus
releas
infect
cell
could
infect
new
epitheli
cell
small
intestin
villi
taken
togeth
data
indic
compound
gue
cure
diarrhea
block
rva
attach
polyphenol
compound
entri
acid
replic
polyphenol
compound
villou
epithelium
rva
infect
elev
proinflammatori
cytokin
tnf
later
cytokin
cytokin
activ
jnk
associ
viru
replic
virusinduc
proinflammatori
gene
express
howev
rotaviru
strain
known
downregul
activ
function
nonstructur
protein
inflammatori
respons
import
host
defens
mechan
pathogen
detriment
often
harm
host
incit
pathogen
present
experi
rva
infect
increas
mrna
express
level
tnf
small
intestin
spleen
piglet
inocul
rva
alon
wherea
gue
treatment
downregul
mrna
express
level
gene
piglet
induct
rva
diarrhea
indic
polynomi
orthogon
contrast
moreov
jnk
gene
inhibit
guetreat
piglet
rva
diarrhea
activ
rvainfect
piglet
without
treatment
data
suggest
gue
treatment
modul
proinflammatori
reaction
lead
allevi
intestin
lesion
exacerb
host
inflamm
known
glycyrrhizin
downregul
proinflammatori
cytokin
inhibit
activ
jnk
gene
virusinfect
cell
notabl
howev
report
show
acid
induc
activ
gener
secret
rvainfect
cell
present
studi
proinflammatori
cytokin
relat
transcript
factor
signal
molecul
inhibit
guetreat
piglet
rva
diarrhea
rvainocul
piglet
without
treatment
although
acid
induc
activ
gener
secret
vitro
possibl
vivo
vivo
inhibitori
effect
proinflammatori
reaction
might
predomin
glycyrrhizin
compound
gue
well
viral
nonstructur
protein
futur
studi
need
address
compound
exert
inflammatori
antiinflammatori
effect
anim
model
current
investig
role
sever
compound
gue
modul
rotaviru
infect
vivo
addit
activ
jnk
gene
constitu
redoxsensit
signal
pathway
therefor
antioxid
alreadi
found
interfer
virusinduc
proinflammatori
gene
express
sinc
glycyrrhizin
known
exert
antioxid
effect
gue
may
interfer
rvainduc
reactiv
oxygen
speci
format
protect
intestin
epitheli
cell
reactiv
oxygen
speci
elicit
rva
infect
conclus
show
report
gue
cure
rvainduc
diarrhea
colostrumsdepriv
piglet
antiinflammatori
antivir
effect
gue
attribut
interact
differ
pharmacolog
activ
compon
gue
sinc
current
avail
antirva
drug
human
anim
use
antirotavir
drug
candid
may
complement
arsen
potenti
drug
treatment
rva
enter
anim
also
human
porcin
strain
origin
isol
fecal
sampl
diarrheic
piglet
cultur
fetal
rhesu
monkey
kidney
cell
clone
deriv
monkey
kidney
cell
viru
titer
determin
cell
cultur
immunofluoresc
assay
monoclon
antibodi
protein
porcin
rotaviru
strain
osu
express
fluoresc
focu
unit
per
millilit
ffuml
dri
root
g
uralensi
extract
methanol
room
temperatur
describ
previous
prepar
dissolv
materi
absolut
ethanol
creat
mgml
stock
stock
solut
mgml
mgml
mgml
made
dilut
stock
autoclav
distil
water
colostrumsdepriv
piglet
obtain
sow
hysterectomi
maintain
isol
unit
previous
describ
use
separ
isol
unit
treatment
group
piglet
fed
everi
hour
diet
consist
steril
commerci
milk
piglet
neg
rotaviru
antibodi
prior
rva
exposur
randomli
divid
eight
group
virusinocul
mocktreat
virusinocul
mgml
gue
treat
virusinocul
mgml
gue
treat
virusinocul
mgml
gue
treat
mockinocul
mocktreat
mockinocul
mgml
gue
treat
mock
inocul
mgml
gue
treat
mockinocul
mgml
gue
treat
group
contain
three
piglet
day
age
piglet
group
oral
inocul
ml
strain
contain
viru
titer
x
ffuml
dpi
piglet
show
sign
diarrhea
among
group
three
group
treat
four
time
daili
mgml
mgml
mgml
gue
day
respect
remain
virusinocul
group
mocktreat
day
age
three
mockinocul
group
treat
four
time
daili
mgml
mgml
mgml
gue
day
respect
control
group
piglet
mockinocul
mocktreat
antivir
effect
gue
evalu
basi
diarrhea
score
histopatholog
lesion
small
intestin
quantit
fecal
viru
shed
express
differ
transcript
factor
cytokin
result
obtain
group
treat
gue
compar
mockinocul
mocktreat
group
piglet
also
observ
sign
advers
effect
drug
administr
studi
perform
approv
univers
anim
care
committe
cnu
fecal
consist
examin
daili
inocul
strain
evalu
antivir
effect
gue
rate
system
use
evalu
fecal
consist
normal
pasti
semimucoid
liquid
profus
diarrhea
fecal
sampl
collect
daili
dilut
time
phosphatebuff
salin
pb
ph
suspens
vortex
centrifug
x
g
min
supernat
collect
store
use
start
volum
centrifug
fecal
suspens
use
rna
extract
viral
rna
extract
kit
bioneer
daejeon
south
korea
accord
manufactur
instruct
piglet
immedi
necropsi
euthanasia
death
intestin
tract
remov
abdomin
caviti
small
larg
intestin
content
collect
necropsi
part
small
larg
intestin
sampl
fix
buffer
formalin
solut
serial
section
paraffin
embed
block
stain
mayer
hematoxylin
eosin
examin
microscop
blind
fashion
histolog
evalu
perform
code
sampl
comparison
made
section
mockinocul
mocktreat
virusinocul
mocktreat
control
score
small
intestin
chang
base
averag
villicrypt
vc
ratio
plu
grade
epitheli
cell
desquam
measur
follow
vc
ratio
normal
vc
mild
vc
moder
vc
mark
vc
sever
vc
desquam
grade
normal
desquam
mild
desquam
cell
tip
villou
epithelium
moder
desquam
upper
villou
epithelium
mark
desquam
lower
villou
epithelium
sever
desquam
crypt
epithelium
ten
randomli
select
villi
crypt
intestin
histolog
section
chosen
determin
mean
lesion
chang
similar
method
describ
previous
use
primer
pair
specif
gene
rva
onestep
realtim
rtpcr
assay
base
sybr
green
detect
carri
quantifi
rna
rva
fecal
sampl
describ
previous
briefli
total
rna
extract
fecal
sampl
process
use
corbett
research
rotorgen
realtim
amplif
system
corbett
research
mortlak
australia
sensimix
onestep
rtpcr
sybr
green
quantac
london
uk
reaction
mixtur
compos
rna
sensimix
onestep
mixtur
forward
revers
primer
green
solut
rnase
inhibitor
final
concentr
unit
final
concentr
mm
rnase
free
water
revers
transcript
perform
min
follow
min
activ
dna
polymeras
threestep
cycl
min
use
rotagen
amount
rvaspecif
rna
fecal
sampl
quantifi
base
standard
curv
deriv
serial
dilut
vitro
transcript
complementari
rna
crna
highest
amplif
rate
defin
automat
initi
exponenti
phase
direct
relationship
cycl
number
log
concentr
rna
molecul
initi
present
rtpcr
reaction
evid
regard
cross
point
result
amplif
curv
threshold
rotogen
softwar
use
set
standard
curv
allow
determin
concentr
rna
present
sampl
use
linear
regress
analysi
data
sampl
prepar
spleen
part
small
intestin
extract
total
rna
carri
describ
elsewher
total
rna
extract
use
rna
isol
reagent
molecular
research
center
cincinnati
oh
usa
isol
rna
revers
transcrib
use
revers
transcript
kit
qiagen
valencia
ca
usa
accord
manufactur
instruct
reduc
discrep
sampl
transcrib
concurr
revers
transcriptas
effici
realtim
pcr
primer
porcin
jnk
design
describ
elsewher
mrna
express
level
jnk
quantifi
realtim
pcr
assay
use
rotagen
corbett
research
sydney
nsw
australia
cdna
twentyf
realtim
pcr
reaction
carri
use
sensimix
onestep
rtpcr
sybr
green
quantac
london
uk
accord
manufactur
instruct
qpcr
condit
perform
describ
elsewher
rel
gene
express
assess
ct
target
gene
ct
intern
control
gene
sampl
target
gene
calibr
target
gene
data
gather
experi
written
mean
standard
deviat
sd
compar
group
mean
differ
paramet
analyz
varianc
order
evalu
signific
differ
group
data
analyz
tukey
multipl
comparison
test
use
minitab
statist
softwar
minitab
state
colleg
pa
usa
level
signific
select
p
determin
oneway
anova
polynomi
orthogon
contrast
proinflammatori
marker
perform
use
statist
version
chicago
illinoi
usa
author
declar
compet
interest
mma
khj
wsl
koc
design
conceiv
experi
particip
data
interpret
wrote
manuscript
jgp
ehr
jyk
yjj
dsk
mh
ky
jhl
sip
contribut
experiment
design
perform
experi
hjk
ybr
sjp
extract
provid
test
materi
author
read
approv
final
manuscript
